Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology and Metabolic Disease Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for SLC7A5 (LAT1) drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen / Cell Line | SLC7A5 Lentivirus Premade Particles For stable cell line construction (Flow Cytometry/Calcium Flux). Sequence Verified. |
View SLC7A5 Products |
| Gene Delivery | SLC7A5 Promise-ORF Full-length ORF for stable expression. |
View SLC7A5 Products |
| Benchmark Ab | Anti-SLC7A5 Recombinant Antibody Recombinant positive control for assay development. |
View SLC7A5 Products |
| Validator | SLC7A5 siRNA Set For knockdown verification and specificity checks. |
View SLC7A5 Products |
| Related Target A | SLC3A2 (CD98hc) Forms a functional heterodimer with SLC7A5 at the plasma membrane. |
View SLC3A2 Products |
| Related Target B | mTOR Downstream metabolic sensor activated by SLC7A5-mediated amino acid influx. |
View mTOR Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Complex Multi-pass Membrane Structure | Lentivirus-mediated stable cell lines preserve native conformation. |
| Heterodimer Dependency (CD98hc) | Co-expression compatible vectors and validated siRNA for specificity. |
| Lack of Controls | High-affinity recombinant benchmark antibodies included. |
| False Positives in Screening | Validated siRNA included for rigorous biological specificity checks. |
Live SLC7A5 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for SLC7A5 (LAT1) therapeutics is intensifying, with major players shifting focus from traditional small molecule inhibitors to targeted biologics like ADCs and bispecific antibodies. As a critical amino acid transporter highly upregulated in various solid tumors, SLC7A5 represents a key metabolic vulnerability. As first-generation small molecule therapies advance through clinical trials, the next wave of R&D is targeting selective tumor delivery and overcoming metabolic compensation mechanisms.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule | J-Pharma (JPH203) | Biliary Tract Cancer, Solid Tumors | Uptake Assay (Need stable cell lines via Lentivirus) |
| ADC | Emerging Biotechs | Refractory Solid Tumors | Internalization Assay (Need native conformation cells) |
| Monoclonal Antibody | Various Academic/Biotech | Pancreatic, Lung Cancers | FACS Binding (Need high-expression stable clones) |